Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q09428: Variant p.Ser1388Tyr

ATP-binding cassette sub-family C member 8
Gene: ABCC8
Feedback?
Variant information Variant position: help 1388 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Serine (S) to Tyrosine (Y) at position 1388 (S1388Y, p.Ser1388Tyr). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from small size and polar (S) to large size and aromatic (Y) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In HHF1. Any additional useful information about the variant.


Sequence information Variant position: help 1388 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 1581 The length of the canonical sequence.
Location on the sequence: help IAPGQKIGICGRTGSGKSSF S LAFFRMVDTFEGHIIIDGID The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         IAPGQKIGICGRTGSGKSSFSLAFFRMVDTFEGHIIIDGID

Rat                           ISPGQKIGICGRTGSGKSSFSLAFFRMVDMFEGRIIIDGID

Slime mold                    IEPKTKVGIVGRTGAGKSSLTQALFRLVEPLRGTIEIDGID
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 1581 ATP-binding cassette sub-family C member 8
Topological domain 1298 – 1581 Cytoplasmic
Domain 1344 – 1578 ABC transporter 2
Alternative sequence 51 – 1581 Missing. In isoform 3.
Helix 1384 – 1389



Literature citations
Monoallelic ABCC8 mutations are a common cause of diazoxide-unresponsive diffuse form of congenital hyperinsulinism.
Saint-Martin C.; Zhou Q.; Martin G.M.; Vaury C.; Leroy G.; Arnoux J.B.; de Lonlay P.; Shyng S.L.; Bellanne-Chantelot C.;
Clin. Genet. 87:448-454(2015)
Cited for: VARIANTS HHF1 MET-511; ASP-716; LYS-824; THR-889; PRO-890; PRO-1352; SER-1378; PHE-1386; TYR-1388; PRO-1389; VAL-1457; ILE-1480; GLU-1505 AND SER-1511; CHARACTERIZATION OF VARIANTS HHF1 MET-511; LYS-824; THR-889; PRO-890; SER-1378; VAL-1457; ILE-1480; GLU-1505 AND SER-1511; FUNCTION; SUBCELLULAR LOCATION;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.